Novo Nordisk has met its primary endpoint in two phase III studies of once-weekly insulin icodec, the Danish pharmaceutical company has announced in a press release.
The two studies, Onwards 3 and Onwards 4, are a part of the Onwards program, which is comprised of 6 studies. With three sub-programs having already reported promising results, there is now only one left, expected to conclude during the second half of 2022.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
ALK to exit Turkish market: "It's bad business if all we get is peanuts"
A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.
Genmab postpones crucial cancer candidate decision following Abbvie exit
For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.
Genmab says new arbitration builds on a straightforward question
”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.
Top news from MedWatch this week
Miss anything?
Analyst: Upgraded ALK sales guidance could still be beaten
Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.
Lead Automation Engineer ABB Sattline/ABB 800XA, AFRY 
Quality coordinator for Aseptic Production, ALK 
Biomarker Operations Lead 
Head of Regulatory Services Denmark 
Open position for a Clinical Trial Manager to join our team at Nykode! 
Medical Advisor (Metabolism) 
Lead Auditor – Senior Quality Assurance Specialist 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Scientist Radiochemistry 
Senior Manager, QA GCP/PV 
Director Regulatory Affairs 
Clinical Trial Manager - Black Swans Exist